FDA PCCP In-Depth Interpretation: The Fast Track for Iterative Updates of AI Medical Devices - Wiselink Group-A More Controllable, Stable, and Future-Oriented Material Direction

Home > News Center > FDA PCCP In-Depth Interpretation: The Fast Track for Iterative Updates of AI Medical Devices

FDA PCCP In-Depth Interpretation: The Fast Track for Iterative Updates of AI Medical Devices

Time：2026-10-22 13:52:42

AI/ML medical devices are characterized by continuous iteration and ongoing model optimization. Under the traditional regulatory framework, every modification that may impact safety and effectiveness requires a new premarket submission, which is time-consuming and costly, severely slowing down the rollout of algorithm iterations. To resolve this conflict, the FDA launched the Predetermined Change Control Plan (PCCP), opening a compliant post-market modification pathway for medical device manufacturers. Today, combining official FDA resources, we break down the underlying logic, core content and applicable boundaries of PCCP.

原

文

链

接

https://www.fda.gov/medical-devices/premarket-submissions-selecting-and-preparing-correct-submission/predetermined-change-control-plans

一、What is Predetermined Change Control Plan (PCCP)

A PCCP is an official document submitted to the FDA together with the device’s initial marketing submission.It specifies in advance the future planned modifications to the device, how the manufacturer will develop, test and implement these modifications, and how the manufacturer will assess the impacts of such changes.The FDA reviews this plan concurrently during the evaluation of the original marketing application. If the PCCP is authorized, subsequent changes strictly implemented in accordance with the approved PCCP do not require separate new marketing submissions for each modification.

Key Takeaway：PCCP is not a blanket pass for arbitrary changes. It is a pre-authorized modification scheme within defined boundaries. Any revisions outside the scope of the plan still require a new submission.

二、Core Value of PCCP

Accelerate product iteration and launch：Allow manufacturers to rapidly deploy pre-planned product optimizations, bringing technological advances to patients sooner.

Reduce regulatory burden for enterprises：Modifications falling within the scope of the approved PCCP are exempt from repeated 510(k)/De Novo/PMA submissions, saving time and submission costs.

Alleviate FDA review workload：Cut down a large volume of repetitive supplemental submissions for reviewers.

Safeguard the safety baseline：Verification, evaluation and risk control rules for all changes are predefined and solidified within the PCCP to ensure the device remains safe and effective over time.

三、Modifications Eligible for Inclusion in PCCP

Revisions that can be incorporated into a PCCP must satisfy all three criteria simultaneously:

Without the PCCP, this modification would otherwise require a new marketing submission.
The modification does not expand the device’s original intended use.
For devices under the 510(k) pathway, the modified device remains substantially equivalent to the predicate device.

Regulatory Basis: FD&C Act Secn 515C, 21 CFtioR 807.81(a)(3), 21 CFR 814.39(a)

四、Three Mandatory Modules of a Complete PCCP

Per FDA official requirements, a valid Predetermined Change Control Plan consists of three core sections. The level of detail shall be consistent with other sections of the marketing submission.

（一）Description of Modifications

Clearly document all planned changes, including planned adjustments to device characteristics, performance parameters and technical specifications. Vague descriptions are prohibited. Generic statements such as “algorithm may be updated” are unacceptable; specific types of modifications must be itemized.

（二）Modification Protocol

Performance assessment activities corresponding to each change, with predefined acceptable acceptance criteria to verify safety and effectiveness after modification; Implementation workflow for rolling out changes; where applicable, procedures for notifying end users of device updates.

（三）Impact Assessment

Impacts of individual modifications and combined multiple modifications; Cascading effects triggered by one modification on other planned changes; Benefits and risks associated with each category of modification; Evidence demonstrating that this protocol can continuously ensure the safety and effectiveness of the medical device.

五、PCCP vs. Traditional Post-Market Modifications

Dimension	Traditional Post-Market Modification	Predetermined Change Control Plan (PCCP)
Authorization Timing	After device clearance/approval; re-evaluate whether a supplemental submission is required once changes occur	Authorized in advance during the original premarket submission stage
Submission Logic	After the change occurs, judge risk and submit new/supplemental applications case-by-case	When changes roll out, execute per the predefined protocol; no repeated submission for in-scope modifications
Binding Terms	Follow post-market modification rules and submission obligations	All revisions must strictly comply with the PCCP document; out-of-scope changes still require new submissions

六、Submission Pathways Compatible with PCCP

PCCP is not an independent submission type. It must be reviewed and authorized alongside the device’s marketing submission. Three pathways are supported, also applicable to combination products led by medical devices:

510(k) (Premarket Notification, Class II Devices)
De Novo (Classification Request for Novel Class II Devices)
PMA (Premarket Approval, High-Risk Class III Devices)

Note：PCCP shall be arranged as an independent section within the submission package and highlighted in the submission cover letter. In the eSTAR electronic submission template, select the corresponding checkbox under the General Device Characteristics section and upload attachments.

七、Products with Authorized PCCP

The FDA maintains a public inventory on its official website. As of the page update date (Oct 20, 2026)，there are 240 publicly listed device entries with authorized PCCPs，covering multiple verticals:

Radiology AI Software：QCT LUNG, ECHOPAC ultrasound software, A2Z-ABDO-TRIAGE and other AI imaging products

Cardiovascular Devices：ablation catheters, AI ECG devices

Clinical Chemistry / IVD：Influenza RT-PCR test kits, microbial susceptibility testing systems, insulin dosing decision support software

It is evident that AI software and Software as a Medical Device (SaMD) are currently the primary use cases for PCCP implementation.

八、Critical Practical Reminders for Manufacturers

PCCP cannot be added retroactively：It must be submitted at the time of the original premarket application. PCCP authorization cannot be supplemented after the device has already gone to market.

Scope boundary awareness matters：PCCP only covers pre-defined planned changes. Any actual modification beyond the documented scope still follows the regular supplemental submission route.

Establish supporting internal SOPs：Authorization of PCCP is not the end of work. Manufacturers shall build complete internal operating procedures, including version traceability, ongoing performance monitoring and rollback mechanisms for abnormal updates.

Reference full official resources：

August 2024 Draft Guidance: Predetermined Change Control Plans for Medical Devices
August 2025 Final Guidance: Submission Recommendations for PCCP for AI Device Software Functions
Supplementary webinars and case documents are available for review on the FDA official website.

九、Closing Remarks

The PCCP framework represents a major regulatory innovation launched by the FDA to accommodate the iterative nature of AI medical devices. It shifts the paradigm from case-by-case retrospective review of changes to pre-approval of change rules + autonomous post-market iteration under approved rules. For AI medical device companies targeting the U.S. market, PCCP has become a highly strategic option. However, it imposes stringent requirements on upfront documentation planning, risk analysis and verification protocol design. Planning for PCCP means mapping out the iteration roadmap, verification criteria and risk control measures well in advance, at the very beginning of the submission project.For further consultation, please reach out to Wiselink.

Previous：UK Officially Confirms Indefinite Recognition of CE-Marked Medical Devices: Dual Pathways of UKCA and CE Run in Parallel Next：Global Fetal & Neonatal Device Market Analysis: Which Segment Should Chinese Medical Device Manufacturers Target for Overseas Expansion

Fill Form

Whether you need more information or wish to cooperate with us, we will guide you through every step of the regulatory process. Subscribe to our newsletter for the latest global regulatory updates.